Sort
46,585 grants matching “heart failure”
Mitochondrial Metabolism in Primary Hyperoxaluria
$437,766Ross P Holmes · University Of Alabama At Birmingham · R01 · FY2015 · DK
The Role of TIM-1: TIM-4 Pathway in Allograft Rejection and Tolerance
$437,750Mohamed H Sayegh · Boston Children'S Hospital · R01 · FY2007 · AI
Novel longevity enhancing pathways regulated by mTOR
$437,727Christian Sell · Drexel University · R01 · FY2024 · AG
The Effect of Sex Hormones on Cardiometabolic Outcomes in Men and Women with Diabetes: The Look AHEAD (Action for Health in Diabetes) Study
$437,724Wendy Lynet Bennett · Johns Hopkins University · R01 · FY2024 · DK
Antiotensin converting enzyme gene expression
$437,669Ganes C. Sen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2011 · HL
Antiotensin converting enzyme gene expression
$437,633Ganes C. Sen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2012 · HL
Dynamic Interactions of Cardiac Troponin and Tropomyosin
$437,624Larry S Tobacman · University Of Illinois At Chicago · R01 · FY2011 · HL
Molecular and Microstructural Imaging of Cardiomyocyte Apoptosis and Autophagy
$437,570David E Sosnovik · Massachusetts General Hospital · R01 · FY2008 · HL
Molecular Regulation of Cardiovascular 7 TM Receptors
$437,565Robert J Lefkowitz · Duke University · R01 · FY2017 · HL
Differential Impacts of Person and System Level Determinants of Health on Dyadic Heart Failure Management: The IMPACT-D Study
$437,562Christopher Sean Lee · Boston College · R21 · FY2024 · NR
Retrotrapezoid nucleus and central chemoreception
$437,554Patrice G. Guyenet · University Of Virginia · R01 · FY2018 · HL
Retrotrapezoid nucleus and central chemoreception
$437,554Patrice G. Guyenet · University Of Virginia · R01 · FY2016 · HL
Retrotrapezoid nucleus and central chemoreception
$437,554Patrice G. Guyenet · University Of Virginia · R01 · FY2015 · HL
Retrotrapezoid nucleus and central chemoreception
$437,554Patrice G. Guyenet · University Of Virginia · R01 · FY2017 · HL
The Influence of Gender on Symptom Characteristics During Acute Coronary Syndrome
$437,534Holli A Devon · University Of California At Davis · R01 · FY2011 · NR
Nicotinamide riboside supplementation for treating elevated systolic blood pressure and arterial stiffness in middle-aged and older adults
$437,530Douglas R Seals · University Of Colorado · R01 · FY2023 · AG
Altered Cell-Cell Coupling in Arrhythmogenic Cardiomyopathy
$437,500Jeffrey E Saffitz · Beth Israel Deaconess Medical Center · R01 · FY2021 · HL
Altered Cell-Cell Coupling in Arrhythmogenic Cardiomyopathy
$437,500Jeffrey E Saffitz · Beth Israel Deaconess Medical Center · R01 · FY2019 · HL
Endoglin: A New Target of Therapy for Heart Failure
$437,500Navin Kumar Kapur · Tufts Medical Center · R01 · FY2018 · HL
Regulation of Ion Channels at BIN1-induced T-tubule Microdomains
$437,500Tingting Hong · Cedars-Sinai Medical Center · R01 · FY2016 · HL
Prevention of Vascular Calcification In Chronic Kidney Disease
$437,500W Charles O'Neill · Emory University · R01 · FY2019 · HL
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection
$437,500Daniel N Streblow · Oregon Health & Science University · R56 · FY2015 · AI
A New Non-Canonical Role for an Alternatively Translated Ion Channel Protein
$437,500Robin Mark Shaw · Cedars-Sinai Medical Center · R01 · FY2017 · HL
Regulation of Ion Channels at BIN1-induced T-tubule Microdomains
$437,500Tingting Hong · Cedars-Sinai Medical Center · R01 · FY2017 · HL
Protein carbamylation and uremic cardiomyopathy in chronic kidney disease
$437,500Anders Hayden Berg · Beth Israel Deaconess Medical Center · R01 · FY2018 · HL